Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
  • A23C9/00—Milk preparations; Milk powder or milk powder preparations
  • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
  • A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
  • A23C9/1465—Chromatographic separation of protein or lactose fraction; Adsorption of protein or lactose fraction followed by elution
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
  • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
  • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
  • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4732—Casein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the invention relates to a method for treating a lactic raw material containing the glycomacropeptide or caseinoglycomacropeptide (hereinafter GMP), with the aim of separating the said GMP.
• GMP glycomacropeptide or caseinoglycomacropeptide
• GMP is a phosphorylated and partially sialylated macropeptide which is formed by the action of a protease, for example rennet on kappa-casein from mammalian milk. It represents approximately 20% by weight of the proteins of the sweet whey obtained after separation of the casein during the manufacture of cheeses.
• GMP GMP at the laboratory level consisting of treating a raw material of lactic origin, such as for example an acid casein or a caseinate, hydrolysed by rennet or else a mild whey from demineralized and delacidized cheese, by trichloroacetic acid so as to precipitate the proteins, then to collect the supernatant, to dialyze it and finally to dry the dialysate.
• a raw material of lactic origin such as for example an acid casein or a caseinate, hydrolysed by rennet or else a mild whey from demineralized and delacidized cheese
• trichloroacetic acid so as to precipitate the proteins
• a process for producing GMP on an industrial scale consists in treating a whey product by ion exchange, in collecting the fraction which has not been adsorbed, in concentrating it and in demineralizing it by ultrafiltration, diafiltration and if necessary reverse osmosis and to collect the GMP.
• a process for producing a protein fraction of whey is described in UK-A-2188526. This consists in treating a dairy product with a strong anionic resin, under conditions such that the proteins and certain peptides of the treated material are adsorbed on the resin non-selectively in the form of complexes. Such complexes are difficult to elute from the resin afterwards.
• the eluate is characterized by the formation of a firm gel at a pH below 4.5 and at room temperature once suspended in water.
• the protein fraction can be used in drinks of the "milkshake" type and in dessert desserts.
• JP-A-07132049 it is proposed to use a weak anionic ion exchange resin whose matrix is hydrophilic to separate the sialylated peptides from the whey.
• the method used consists in passing the raw material, the pH of which has been previously adjusted in a precise manner, to a value of 4 to 6, over a hydrophilic macomolecular support consisting of a natural polysaccharide or a polyvinyl synthetic, grafted with basic exchanger groups.
• the supports used as a matrix are not easily applicable industrially.
• the object of the invention is the selective separation of GMP from the other components of lactic materials in a simple operation on an industrial scale with a high yield.
• the invention therefore relates to a method of treatment by ion exchange of a liquid lactic raw material containing GMP, in order to collect on the one hand a product usable directly as a protein source and on the other hand GMP under purified form, characterized in that it comprises the following stages: i) decationization of the liquid raw material, so that the pH has a value of 1 to 4.5, ii) bringing said liquid into contact with a resin weak anionic hydrophobic matrix, predominantly in alkaline form up to a stabilized pH, iii) Separation of the resin and the liquid product which is collected and iv) Desorption of GMP from the resin.
• lactic raw material there can be used in the process according to the invention any product or by-product containing GMP.
• any product or by-product containing GMP we can cite as an indication:
• demineralized sweet whey concentrate for example by electrodialysis, ion exchange, reverse osmosis, electrodeionization or a combination of these methods,
• a preferred raw material is a mild whey from a preconcentrated cheese dairy, preferably at 10-23% by weight and decationized or completely deionized, that is to say decationized and de-anionized.
• Another choice material of choice is a sweetened and decationated sweet whey protein concentrate.
• raw materials can be in liquid form or in powder form and in the latter case they are dispersed in water, preferably demineralized for further processing.
• These raw materials can come from ruminant milk such as goat cow, sheep or buffalo.
• the liquid raw material is placed in the presence of weak anionic resin in a reactor with moderate stirring at a temperature ⁇ 50 ° C., preferably between 0 and 15 ° C.
• the stirring must be just necessary for the fluidization of the resin bed. This can be produced for example by an agitator or, preferably by the introduction of a stream of fluid, for example air or nitrogen under pressure from the bottom of the reactor.
• Any anion exchange resin can be used whose matrix is hydrophobic and whose exchange groups are weakly basic in the form of a gel, macroporous or macroreticulated, preferably polystyrene or polyacrylic, particularly based on polystyrene divinylbenzene copolymer and preferably macroreticulated. for reasons of resistance to osmotic shocks.
• the active groups are generally primary to tertiary amines. Such a resin must be predominantly in alkaline form (hereinafter referred to as OH " form) and therefore its active sites must have been preferably regenerated to a large extent in this form.
• the active sites of the resin are exchanged for GMP molecules, which produces a gradual increase in the pH of the treated liquid, up to a final stabilized value, for example from 4.5 to 5.5 depending on the raw material used.
• the duration of the operation and the respective quantities of resin and of treated liquid are chosen according to the composition of the starting product and the quantity of GMP desired. This operation lasts from 1 to 10 hours, for example approximately 4 hours.
• the respective proportions of resin and liquid to be treated may vary greatly and are, in volume from 1: 1 to 1: 30 and preferably from 1: 1 to 1: 10, depending on the desired degree of separation of the GMP.
• the liquid can be percolated in a column filled with the resin, collect the treated liquid and recover the GMP adsorbed on the resin by elution. This can be done continuously or semi-continuously, for example by extracting the saturated resin from the column against the current and replacing it with freshly regenerated resin.
• the preceding embodiments can be combined, in a reactor and in a column, for example by using a mixed device, the upper part of which is a reactor provided with means for stirring or for producing a fluidized bed containing the resin, separated by a grid or filter of a lower part consisting of a column where it is possible to carry out, at the end of the treatment, the recovery of the resin, for example by decantation, the withdrawal of the treated liquid.
• a mixed device the upper part of which is a reactor provided with means for stirring or for producing a fluidized bed containing the resin, separated by a grid or filter of a lower part consisting of a column where it is possible to carry out, at the end of the treatment, the recovery of the resin, for example by decantation, the withdrawal of the treated liquid.
• the liquid thus treated can be concentrated, for example by evaporation, then dried, for example by spraying in a drying tower.
• the powder thus obtained advantageously serves as a protein raw material in the preparation of infant products and is remarkable because of its profile in desired amino acids, its aminogram showing a depletion in threonine and an enrichment in aromatic amino acids, such as tryptophan.
• the resin is first treated by washing, for example with demineralized water, then if necessary with a dilute saline solution or a dilute acid solution and rinsed with demineralized water.
• the actual desorption of GMP takes place with an aqueous solution of acid, base or salt, preferably with a basic aqueous solution, for example NaOH, KOH or Ca (OH) 2 , advantageously of concentration ⁇ 8 % by weight, preferably 0.5 to 3%, followed by washing with demineralized water.
• aqueous solution of acid, base or salt preferably with a basic aqueous solution, for example NaOH, KOH or Ca (OH) 2 , advantageously of concentration ⁇ 8 % by weight, preferably 0.5 to 3%, followed by washing with demineralized water.
• the eluate and the washing waters are then joined and demineralized, for example by ultrafiltration or nanofiltration on a membrane with an average cut-off area of around 3000 dalton and the retentate is dried, for
• the GMP thus obtained is substantially free of fat and lactose and poor in whey protein.
• It preferably contains, by weight: ⁇ 1% fat,
• GMP can be used in its known applications, for example for its biological properties in oral, parenteral or subcutaneous pharmaceutical compositions as an anti-thrombotic, anti-diarrheal or anti-bacterial agent or preferably as an anti-plaque and anti -caries in dental hygiene compositions, or in food, for example confectionery products for its anti-plaque and anti-caries properties, for its functional properties of emulsifying, gelling or foaming agent or for its dietetic properties , for example in infant anti-phenylketonuria compositions because it does not contain phenylalanine.
• a significant advantage of the method according to the invention is that there is no reduction in the performance of the resin or fouling thereof, even after up to 150 treatment cycles.
• the reactor 1 For the treatment, the reactor 1 is used which consists in its upper part of a main tank 2 communicating in its lower part with a compartment 3 of smaller diameter than that of the tank 2.
• the tank 2 is provided with a conduit d supply of flushing liquid 4, supply of pressurized gas 5, safety valve 6 for regulating the gas pressure in the reactor 1.
• the tank 2 At a level close to its base the tank 2 is provided with '' a strainer 7 and a liquid withdrawal duct 8.
• the reactor is provided with a pH meter 9, a gas supply 10 and communicates by a three-way valve 11 with a pipe 12 for supplying the liquid to be treated and a pipe for discharge 13 for the treated liquid.
• the compartment 3 is provided with a grid or a perforated plate 14 whose role is to collect the resin beads 15.
• a duct 16 for drawing off brings the liquid through the pump 17 to the buffer tank 18 provided with a level control device 19 and beyond towards the conduit 20 via the pump 21.
• the conduit 20 is connected either to the conduit 12 , or to the drainage overflow 22.
• a bovine sweet whey protein concentrate conventionally treated by electrodialysis and decationated on strong cationic resin, is dispersed in deionized water so that the solution has a dry matter content of 6.5%.
• the concentrate has the following composition:
• the air supply is then cut at 10 and air is introduced from the top of the reactor at 5 above the liquid level 24, which has the effect of pushing the liquid and settling the resin beads in the lower part 3 of the reactor 2 where they are retained by the grid 14.
• the liquid treated by gravity is drawn off through the pipe 8 and through the pipe 16 via the pump 17 towards the buffer tank 18 and it is discharged via line 20 by means of pump 21 and beyond towards the outlet via lines 12 and 13.
• the concentrate is dried by spraying in a drying tower (these operations not being shown).
• HPLC high performance liquid chromatography
• the reactor and the resin are washed with deionized water from line 25 and valve 26, then line 4 through the reactor to the outlet via lines 12 and 13.
• the GMP is eluted with twice 40 l of 2% aqueous NaOH solution distributed through line 27 and valve 28 and rinsed with 30 l of deionized water.
• the whole is concentrated to a volume of 25 1 by ultrafiltration or nanofiltration with a nominal cut-off membrane of 3,000 dalton, then the retentate is dried by lyophilization (these operations n (not shown) and 750 g of GMP are obtained, which corresponds to a yield of 82% relative to the starting GMP.
• the resin undergoes an acid regeneration after the alkaline regeneration once the equivalent of 10 volumes of resin bed has been treated.
• a concentrated aqueous solution of HCl is brought in via line 29 and valve 30, respectively for water.
• the resin is then put into OH " form by passing a concentrated aqueous solution of NaOH from the conduits 27, respectively 25 for the water, then 4, and then leaves the reactor 1 via the conduit 16, is taken up by the pump. 17 to the buffer tank 18, then by the pump 21 and discharged through the conduit 20 and the overflow 22 towards the treatment of the effluents. Following this operation, the resin is ready for another treatment cycle.
• a soft bovine whey is used, previously concentrated at 17% dry matter, then demineralized by electrodialysis, decationated on a column of strong cationic resin, de-anionized on a column of weak anionic resin and spray-dried in the drying tower, of the composition indicated above. after: %
• This demineralized whey powder is dissolved in deionized water. After decationation, the solution has an initial pH of 3.8. In the previous installation, 392 kg of this solution are treated at a temperature of 8 ° C. with stirring in the reactor in the presence of 23 kg of weak anionic resin of hydrophobic matrix based on polystyrene (IMAC HP 661 (R) , Rohm & Haas, regenerated in OH " form) for 4 h. The stabilization of the pH at 4.89 indicates the end of the reaction. The liquid is then withdrawn and the resin is collected as before. After concentration of the liquid at 45% of dry matter by evaporation, the concentrate is spray dried in a drying tower.
• IMAC HP 661 (R) weak anionic resin of hydrophobic matrix based on polystyrene
• the resin is washed successively with deionized water, with 30 l of a 0.5% aqueous solution of HCl and with 30 l of deionized water, then the GMP is eluted with twice 40 1 of 2% aqueous Ca (OH) 2 solution and rinsed with 30 1 of deionized water.
• the whole is concentrated to a volume of 25 1 by ultrafiltration with a nominal cut-off membrane of 3,000 dalton, then the retentate is dried by lyophilization and one obtains 900 g of GMP, which corresponds to a yield of 80% compared to the starting GMP.
• the resin is washed successively with deionized water, with 50 l of an aqueous solution at 0.05% NaCl and twice 50 l of deionized water, then the GMP is eluted with twice 25 l of 0.6% KOH aqueous solution and rinsed with 10 l of deionized water.
• the whole is concentrated to a volume of 25 1 by ultrafiltration with a nominal cut-off membrane of 3,000 dalton, then the retentate is dried by lyophilization and we obtain 175 g of GMP, which corresponds to a yield of 80% compared to the starting GMP.
• the whey protein permeate thus treated contains 1.75% protein.
• Analysis of its aminogram shows a profile characterized by a 20% decrease in threonine and a 50% increase in tryptophan.
• the resin is washed with 1 liter of deionized water, then the GMP is eluted with 50 ml of 0.6% NaOH aqueous solution, then rinsed with 20 ml of deionized water. After joining the volumes of eluate and rinsing, the whole is concentrated by ultrafiltration with a nominal cut-off membrane of 3,000 dalton, then the retentate is dried by lyophilization and 870 mg of GMP are obtained.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Biochemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Medicinal Chemistry (AREA)
• Toxicology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Birds (AREA)
• Zoology (AREA)
• Analytical Chemistry (AREA)
• Dairy Products (AREA)
• Peptides Or Proteins (AREA)
• Confectionery (AREA)
• Cosmetics (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=8228378

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (64)

Citations (7)

Family Cites Families (5)

• 1997
  • 1997-05-27 EP EP97201607A patent/EP0880902A1/fr not_active Withdrawn
• 1998
  • 1998-05-22 EP EP98930751A patent/EP0986312B1/fr not_active Expired - Lifetime
  • 1998-05-22 WO PCT/EP1998/003176 patent/WO1998053702A1/fr not_active Ceased
  • 1998-05-22 AU AU81077/98A patent/AU746520B2/en not_active Expired
  • 1998-05-22 BR BRPI9809171-9A patent/BR9809171B1/pt not_active IP Right Cessation
  • 1998-05-22 DE DE69836909T patent/DE69836909T2/de not_active Expired - Lifetime
  • 1998-05-22 CA CA002288184A patent/CA2288184C/en not_active Expired - Fee Related
  • 1998-05-22 JP JP50025199A patent/JP4286325B2/ja not_active Expired - Fee Related
  • 1998-05-22 NZ NZ500848A patent/NZ500848A/en not_active IP Right Cessation
• 1999
  • 1999-11-29 US US09/450,217 patent/US6787158B1/en not_active Expired - Lifetime

Patent Citations (7)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events